Polynucleotides, Compositions, and Methods for Genome Editing Involving Deamination
AssigneeIntellia Therapeutics, Inc.
InventorsChristian Dombrowski, William Frederick Harrington, Ruan Oliveira
Life of this patent
Estimating the term…
Loading patent…
AssigneeIntellia Therapeutics, Inc.
InventorsChristian Dombrowski, William Frederick Harrington, Ruan Oliveira
Estimating the term…
Polynucleotides, polypeptides, compositions, and methods for genome editing using deamination are provided. An mRNA containing an open reading frame (ORF) encoding a polypeptide is provided herein. The polypeptide includes a cytidine deaminase and an RNA-guided nickase, and does not include a uracil glycosylase inhibitor (UGI). A composition provided herein may include two different mRNAs. The first mRNA includes an ORF encoding a cytidine deaminase and an RNA-guided nickase, and the second mRNA includes an ORF encoding uracil glycosylase inhibitor (UGI).
A composition comprising a first mRNA comprising a first open reading frame encoding a polypeptide comprising a cytidine deaminase and an RNA-guided nickase, and a second mRNA comprising a second open reading frame encoding a uracil glycosylase inhibitor (UGI), wherein the second mRNA is different from the first mRNA, optionally wherein the composition comprises lipid nanoparticles.
A method of modifying a target gene comprising delivering to a cell a first mRNA comprising a first open reading frame encoding a first polypeptide comprising a cytidine deaminase and an RNA-guided nickase, a second mRNA comprising a second open reading frame encoding a uracil glycosylase inhibitor (UGI), wherein the second mRNA is different from the first mRNA, and at least one guide RNA (gRNA).
An mRNA comprising an open reading frame encoding a polypeptide comprising a cytidine deaminase and an RNA-guided nickase, wherein the polypeptide does not comprise a uracil glycosylase inhibitor (UGI).
A method of modifying at least one cytidine within a target gene in a cell, comprising expressing in the cell or contacting the cell with:
An engineered cell comprising at least one base edit and/or indel, wherein the base edit and/or indel is made by contacting a cell with a composition comprising a first mRNA comprising a first open reading frame encoding a polypeptide comprising a cytidine deaminase and an RNA-guided nickase, and a second mRNA comprising a second open reading frame encoding a uracil glycosylase inhibitor (UGI), wherein the second mRNA is different from the first mRNA.
A method of modifying a target gene in a cell, comprising delivering to the cell one or more lipid nucleic acid assembly compositions, optionally lipid nanoparticles, comprising:
A polypeptide comprising a cytidine deaminase and an RNA-guided nickase, wherein the polypeptide does not comprise a uracil glycosylase inhibitor (UGI).
A composition comprising a first polypeptide comprising a cytidine deaminase and an RNA-guided nickase, wherein the first polypeptide does not comprise a uracil glycosylase inhibitor (UGI), and a second polypeptide comprising a UGI, wherein the second polypeptide is different from the first polypeptide.
A kit comprising the mRNA, RNP, composition, or polypeptide of any of 1-4, 8-11, 19-69, 74, and 126-130.
The mRNA, RNP, composition, method, use, cell, or engineered cell of any one of 1-132, wherein the polypeptide comprising a cytidine deaminase and an RNA-guided nickase includes:
A method of altering a DNA sequence within a TRAC gene, comprising delivering to a cell:
A method of reducing the expression of a TRAC gene, comprising delivering to a cell:
A method of immunotherapy comprising administering a composition comprising an engineered cell to a subject,
A method of altering a DNA sequence within a TRBC1 and/or TRBC2 gene, comprising delivering a composition to a cell, wherein the composition comprises:
A method of reducing the expression of a TRBC1 and/or TRBC2 gene, comprising delivering a composition to a cell, wherein the composition comprises:
A method of immunotherapy comprising administering a composition comprising an engineered cell to a subject,
A composition comprising:
A composition comprising:
An engineered cell which has reduced or eliminated surface expression of TRAC, comprising a genetic modification in a human TRAC gene, wherein the genetic modification comprises a modification of at least one nucleotide within the genomic coordinates selected from:
An engineered cell which has reduced or eliminated surface expression of TRBC1/2, comprising a genetic modification in a human TRBC1/2 gene, wherein the genetic modification comprises a modification of at least one nucleotide within the genomic coordinates selected from:
A lipid nucleic acid assembly composition comprising an mRNA comprising an open reading frame encoding a polypeptide comprising a cytidine deaminase and an RNA-guided nickase, wherein the polypeptide does not comprise a uracil glycosylase inhibitor (UGI).
One or more lipid nucleic acid assembly compositions, optionally lipid nanoparticles, comprising:
Dependencies are inferred from the claim text.